Insider · CIK 0001808322

Lachey Jennifer

Reports to the SEC for 1 company · LEXINGTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001808322

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-07-15	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+46K sh	$0.30	+$13.8K	141,134
2022-07-15	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−46K sh	$30.00	−$1.38M	95,100
2022-07-15	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−46K sh	—	—	8,755
2022-07-13	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+1,916 sh	$0.30	+$574.8	93,184
2022-07-13	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,916 sh	$30.00	−$57.5K	95,100
2022-07-13	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−1,916 sh	—	—	54,789
2022-06-14	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+9,400 sh	$0.30	+$2,820	95,100
2022-06-14	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−9,400 sh	—	—	56,705
2022-05-11	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+5,300 sh	$0.30	+$1,590	91,000
2022-05-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−3,398 sh	$41.26	−$140K	87,602
2022-05-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−944 sh	$42.49	−$40.1K	86,658
2022-05-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−719 sh	$43.32	−$31.1K	85,939
2022-05-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−223 sh	$44.23	−$9,863.29	85,716
2022-05-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−16 sh	$45.45	−$727.2	85,700
2022-05-11	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−5,300 sh	—	—	66,105
2022-04-11	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+5,300 sh	$0.30	+$1,590	91,000
2022-04-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,417 sh	$61.37	−$87K	89,583
2022-04-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,009 sh	$62.32	−$62.9K	88,574
2022-04-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−2,315 sh	$63.50	−$147K	86,259
2022-04-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−559 sh	$64.15	−$35.9K	85,700
2022-04-11	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−5,300 sh	—	—	71,405
2022-04-04	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+7,950 sh	$0.30	+$2,385	93,650
2022-04-04	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−7,950 sh	$60.00	−$477K	85,700
2022-04-04	KROSKeros Therapeutics, Inc. · of Shares Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−7,950 sh	—	—	76,705
2022-03-11	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,650 sh	$0.30	+$795	88,350
2022-03-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,062 sh	$52.43	−$55.7K	87,288
2022-03-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−713 sh	$53.36	−$38K	86,575
2022-03-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−875 sh	$54.54	−$47.7K	85,700
2022-03-11	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,650 sh	—	—	84,655
2022-02-11	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,650 sh	$0.30	+$795	88,350
2022-02-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,073 sh	$51.50	−$55.3K	87,277
2022-02-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,378 sh	$52.35	−$72.1K	85,899
2022-02-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−199 sh	$53.10	−$10.6K	85,700
2022-02-11	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,650 sh	—	—	87,305
2022-01-21	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+50K sh	—	—	50,000
2022-01-11	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,650 sh	$0.30	+$795	88,350
2022-01-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−320 sh	$52.01	−$16.6K	88,030
2022-01-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,196 sh	$53.56	−$64.1K	86,834
2022-01-11	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,134 sh	$54.45	−$61.7K	85,700
2022-01-11	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,650 sh	—	—	89,955
2022-01-05	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,650 sh	$0.30	+$795	88,350
2022-01-05	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−2,650 sh	$60.00	−$159K	85,700
2022-01-05	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,650 sh	—	—	92,605
2021-12-15	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+735 sh	$0.30	+$220.5	86,435
2021-12-15	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−735 sh	$50.00	−$36.8K	85,700
2021-12-15	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−735 sh	—	—	95,255
2021-12-13	KROSKeros Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+1,915 sh	$0.30	+$574.5	87,615
2021-12-13	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,518 sh	$50.11	−$76.1K	86,097
2021-12-13	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−390 sh	$52.22	−$20.4K	85,707
2021-12-13	KROSKeros Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−7 sh	$53.64	−$375.48	85,700

Recent filings

Accepted (ET)
Jul 194
Lachey Jennifer0001209191-22-042573
SEC(opens sec.gov)
Jul 154
Lachey Jennifer0001209191-22-042253
SEC(opens sec.gov)
Jun 144
Lachey Jennifer0001209191-22-036800
SEC(opens sec.gov)
May 134
Lachey Jennifer0001209191-22-028889
SEC(opens sec.gov)
Apr 134
Lachey Jennifer0001209191-22-024290
SEC(opens sec.gov)

Companies

Keros Therapeutics, Inc.Chief Scientific OfficerKROS

Address

C/O KEROS THERAPEUTICS, INC. 99 HAYDEN AVENUE, SUITE 120, BUILDING E

LEXINGTON, MA, 02421